METHOD OF LUNG CANCER TREATMENT Russian patent published in 2015 - IPC A61K31/7125 A61P35/00 

FIELD: medicine.

SUBSTANCE: additional intravenous introductions of preparation of recombinant hybrid protein of tumour necrosis factor alpha - thymosin-alpha-1 (TNF-T)-Refnot before starting chemotherapy and after finishing chemotherapy. On the first day of the course of induction (neoaduvant) chemoimmunotherapy content of Refnot preparation vial is dissolved with 2 ml of injection water with further dilution of obtained solution in vial with 200 ml of isotonic (0.9%) sodium chloride solution in dose 50.000 IU per m² of patient's body, but not more than 100.000 IU per one introduction, with immediate introduction after solution preparation intravenously by drop infusion during 1-hour infusion. On the second day infusion of cytoxics is performed. Analogous Refnot infusion is performed a day after chemotherapy completion.

EFFECT: method makes it possible to reduce toxic side reactions and improve tolerability of induction polychemotherapy.

2 ex